“
“A simple, sensitive and reproducible RP-HPLC method was developed and validated for the simultaneous determination of atorvastatin and gemfibrozil in human plasma. After a single step liquid-liquid extraction of both the drugs with acetonitrile, the separation was accomplished on a Merck C 18 column (250 x 4.6, 5 mu m). Diode array detection at a wavelength of 240 nm was carried out with a mobile phase comprising of a mixture of 0.1M ammonium acetate buffer (pH 5.0) and acetonitrile in the ratio of (45:55, v/v). The method was linear in the concentration range of 0.1-20 mu g/ml

for atorvastatin and 6-1200 mu g/ml for gemfibrozil with correlation coefficient between 0.9997 and 0.9976. The limit of detection was 0.03 mu g/ml for atorvastatin and 1.8 mu g/ml for gemfibrozil. The limit of quantitation was 0.1 mu g/ml for atorvastatin Galunisertib chemical structure NCT-501 and 6 mu g/ml for gemfibrozil. The average recovery of both the analytes was greater than 75 %. The method was validated in terms of linearity, recovery, precision, specificity, LOD/LOQ values and stability of solutions and it was applied successfully

for the determination of atorvastatin and gemfibrozil in spiked human plasma.”
“Aim Quantitative changes of cell-free fetal DNA in maternal plasma as an indicator for impending pre-eclampsia was reported in different studies. Cell-free fetal nucleic acids can be detected in maternal circulation during pregnancy. Our aim was to determine the higher rate of fetal DNA levels in maternal blood in pre-eclampsia compared to normal pregnancies and the clinical use of real-time polymerase chain reaction (PCR) in the Turkish population as a marker. Material and Methods According to their gestational ages, the plasma levels of Sonidegib Stem Cells & Wnt inhibitor 30 pre-eclamptic women at 2640 weeks of pregnancy were matched with 18 healthy pregnant women. Cell-free

fetal DNA levels in maternal plasma were compared using real-time PCR technology. For the quantitative measurement of fetal DNA from maternal blood, the relative quantification PCR process was applied to all samples, using SRY and GAPDH genes. These patients were classified as pre-eclamptic and control groups and were matched according to weeks of pregnancy. Results Free fetal DNA levels of 30 pre-eclamptic patients were compared to healthy pregnant women and an average 3.06-fold increase was observed. During the second trimester, free fetal DNA levels were 1.5 times higher in pre-eclamptic patients. This increase was 3.5-fold during the third trimester. The DNA increase of pre-eclamptic patients was 4.1-fold and 3.4-fold during 29th33rd and 34th40th weeks, respectively. Conclusions Cell-free fetal DNA in maternal blood could be used as a marker for identifying subjects at increased risk of developing pre-eclampsia.”
“Bulbs of Fritillaria ussuriensis Maxim., usually known as Bulbus Fritillariae ussuriensis, (BFU) has been used as antitussive, antiasthmatic and expectorant in traditional herbal medicine.

No related posts.